This Article Full Text Full Text (PDF) eLetters: Submit a response to this article Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services E-mail this article link to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints/Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Jackson, G. H. Search for Related Content PubMed PubMed Citation Articles by Jackson, G. H.

Renal Safety of Ibandronate

Department of Haematology, University of Newcastle-Upon-Tyne, Newcastle-Upon-Tyne, United Kingdom

Key Words. Bisphosphonates • Ibandronate • Bone metastases • Renal safety • Renal impairment

Correspondence: Graham Jackson, M.D., Department of Haematology, University of Newcastle-Upon-Tyne, R.V.I., Queen Victoria Road, Newcastle-Upon-Tyne, United Kingdom, NE1 4LP. Telephone: 191-282-4763; Fax: 191-282-5042; e-mail: graham.jackson{at}ncl.ac.uk

Despite their efficacy in treating complications associated with metastatic bone disease, there are concerns about the potential nephrotoxicity of certain i.v. bisphosphonates for the long-term management of cancer patients. Clinical data suggest, however, that i.v. ibandronate (Bondronat^®; F. Hoffman-La Roche Ltd., Basel, Switzerland, http://www.roche.com), unlike other bisphosphonates, has a renal safety profile comparable with that of placebo. In a 2-year, phase III study of patients with breast cancer metastatic to bone, the incidence of adverse renal events in patients treated with 6 mg i.v. ibandronate was low and comparable with that of placebo (4% versus 4.5% with placebo). Two-year assessments of time to serum creatinine increase also demonstrated renal safety comparable with that of placebo (patients with creatinine increase: 6% versus 12% with placebo). Long-term (4-year) renal safety of ibandronate was demonstrated in a 2-year extension of the trial. Phase II, open-label studies show that intensive ibandronate dosing does not compromise renal safety in patients with metastatic bone pain from a variety of tumor types. In addition, i.v. ibandronate is well tolerated, with no evidence of renal toxicity in multiple myeloma and urologic cancer patients with existing renal impairment. The potential nephrotoxicity of some bisphosphonates has prompted additional renal safety precautions in product labeling for these agents. The precautions are not, however, contained in the label for ibandronate, which may thus simplify patient management.

This article has been cited by other articles:

				K. Olson and C. Van Poznak Significance and impact of bisphosphonate-induced acute phase responses Journal of Oncology Pharmacy Practice, December 1, 2007; 13(4): 223 - 229. [Abstract] [PDF]

				J. Cunningham Bisphosphonates in the renal patient Nephrol. Dial. Transplant., June 1, 2007; 22(6): 1505 - 1507. [Full Text] [PDF]

				D Aguiar Bujanda, U Bohn Sarmiento, M. Cabrera Suarez, and J Aguiar Morales Assessment of renal toxicity and osteonecrosis of the jaws in patients receiving zoledronic acid for bone metastasis Ann. Onc., March 1, 2007; 18(3): 556 - 560. [Abstract] [Full Text] [PDF]

				J.-J. Body Bisphosphonates in Metastatic Bone Disease: Renal Safety Matters Oncologist, October 1, 2005; 10(suppl_1): 1 - 2. [Full Text] [PDF]